Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-005892-10 | EudraCT Number | ||
| 80202135EDI1001 | Other Identifier | Janssen Research & Development, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of nipocalimab following subcutaneous (SC) administration compared with intravenous (IV) administration in healthy participants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part 1: Single Dose Cohorts | Experimental | Participants will receive subcutaneous (SC) injection or intravenous (IV) infusion of nipocalimab or placebo in single ascending doses on Day 1 in Cohorts 1-6 and SC administration in optional Cohorts 7-8. |
|
| Part 2: Multiple Dose Cohorts | Experimental | Participants will receive up to 4 weekly SC injections of nipocalimab or placebo on Days 1, 8, 15, and 22 in Cohort 1 or 4 biweekly SC injections on Days 1, 15, 29, and 43 in optional Cohort 2. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nipocalimab | Drug | Participants will receive IV infusion or SC injection of nipocalimab. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. | Up to Day 85 |
| Percentage of Participants with Serious Adverse Event (SAE) | A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. | Up to Day 85 |
| Percentage of Participants with Reasonably Related AEs | Percentage of participants with reasonably related AEs will be reported. Reasonably related AE is an AE that has a casual relationship with the pharmaceutical/biological agent under study. | Up to Day 85 |
| Percentage of Participants with AEs Leading to Discontinuation of Study Intervention | Percentage of participants with AEs leading to discontinuation of study intervention will be reported. The participants were discontinued from the study by the investigator if the safety reasons or tolerability reasons such as an AE, it is in the best interest of the participant to discontinue study intervention. | Up to Day 85 |
| Percentage of Participants with Adverse Events of Special Interest (AESIs) | Percentage of participants with AESIs will be reported. Treatment-emergent AEs associated with the following situations are considered as AESI; a) severe or medically significant or immediately life-threatening infections requiring intravenous (IV) anti-infective or operative/invasive intervention or requiring hospitalization or prolongation of existing hospitalization; b) hypoalbuminemia with albumin less than (<) 20 grams per liter (g/L). Treatment-emergent AEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Serum Concentration of Nipocalimab | Serum samples will be analyzed to determine concentrations of nipocalimab using a validated, specific, and sensitive immunoassay method. | Up to Day 85 |
| Change from Baseline in Immunoglobulin (Ig) Levels Over Time |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| PRA Health Sciences | Groningen | NZ 9728 | Netherlands |
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinicaltrials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other | Participants will receive IV infusion or SC injection of placebo. |
|
| Up to Day 85 |
| Number of Participants with Vital Signs Abnormalities | Number of participants with vital signs abnormalities including body temperature, pulse/heart rate, respiratory rate, blood pressure will be reported. | Up to Day 85 |
| Number of Participants with Electrocardiogram (ECG) Abnormalities | Number of participants with ECG abnormalities will be reported. | Up to Day 85 |
| Number of Participants with Clinical Laboratory Abnormalities | Number of participants with clinical laboratory abnormalities related to hematology, serum chemistry and urinalysis will be reported. | Up to Day 85 |
| Number of Participants with Subcutaneous (SC) Injection-site Reactions | Number of participants with SC injection-site reactions will be reported. An injection-site reaction is any AE at a SC study intervention injection-site. | Up to Day 85 |
Change from baseline in Ig levels over time will be reported.
| Baseline to Day 85 |
| Number of Participants with Antibodies to Nipocalimab | Number of participants with anti-drug antibodies to nipocalimab will be reported. | Up to Day 85 |